French Innovative Leukemia Organisation

This study tested whether a combination of two targeted drugs (venetoclax and ibrutinib) works better than standard chemotherapy (FCR) for people with intermediate-risk chronic lymphocytic leukemia (CLL) who have not been treated before. About 120 fit adults took part. The treatm…

This study tested a chemotherapy-free treatment for people with untreated chronic lymphocytic leukemia (CLL). Participants received two drugs (ibrutinib and obinutuzumab) for nine months. If their cancer was in deep remission, they continued ibrutinib alone; if not, they got addi…

This study looked at 152 adults with chronic lymphocytic leukemia (CLL) whose cancer stopped responding to targeted drugs like ibrutinib and venetoclax. Researchers collected data on which treatments were used next and how well they worked. The goal was to understand the best way…